Fresenius announces FDA and EMA acceptance for vedolizumab biosimilar
The proposed biosimilar PB016 targets inflammatory bowel diseases like ulcerative colitis and Crohn's disease.
See the latest news and media coverage for Fresenius. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global healthcare group
fresenius.comLast updated
In short: Fresenius advanced its biopharma portfolio with new biosimilar approvals and launches, while confirming its 2026 financial guidance.
The proposed biosimilar PB016 targets inflammatory bowel diseases like ulcerative colitis and Crohn's disease.
The fund will invest in early-stage to growth-stage healthcare startups, providing capital and expertise.
The state-of-the-art facility accelerates product development and strengthens commitment to patient care.
Dividend of €1.05 per share approved with 99.99% majority, other proposals also passed.
Fresenius receives approval for biosimilar candidate PB016 in the USA and EU. At the same time, the dialysis subsidiary starts a US research program.
Fresenius Medical Care (FMC) has continued to work through the second tranche of its ongoing share buyback program and between July 20 and 24, 2026, a total of 241,000 of its own shares...
BNP Paribas Exane downgrades Fresenius Medical Care stock rating on dialysis volume concerns...
With an upward movement of 1.94 percent, the share of Fresenius SE & Co. KGaA manages to reach the upper third of the Dax.
Track Fresenius and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.